Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Natrol Q2 earnings

This article was originally published in The Tan Sheet

Executive Summary

Natrol reported net income of $100,000 on net sales of $16.6 mil. during the second-quarter (ended June 30) marking the company's "second consecutive quarter of profitability," Natrol President and CEO Wayne Bos said Aug. 14. The gains represented a turnaround from the first two quarters of 2005 when Natrol reported a net loss of $300,000 on net sales of $37.3 mil. "We have achieved profitability by being sharply-focused on the core business," Bos said...

You may also be interested in...

Natrol Sees More Deals In The Future; Looks To Tailor, Balance Portfolio

An exclusive manufacturing and distribution deal with H57 Nutrition for Original South African H57 Hoodia is a feather in Natrol's cap following several acquisitions and licensing deals in the past three weeks

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts